Leerink Partners analyst Marc Goodman maintained a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) on Monday, setting a price target of $26, which is approximately 25.73% above the present share price of $20.68.
Goodman expects ACADIA Pharmaceuticals to post earnings per share (EPS) of -$0.27 for the fourth quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in ACADIA Pharmaceuticals, with an average price target of $24.75.
The analysts price targets range from a high of $35 to a low of $18.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $115.22 million and a net profit of -$43.71 million. The company's market cap is $3.32 billion.
According to TipRanks.com, Leerink Partners analyst Marc Goodman is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.3% and a 47.65% success rate.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.